Sodium Tetradecyl Sulfate
In the US, Sodium Tetradecyl Sulfate (sodium tetradecyl sulfate systemic) is a member of the drug class sclerosing agents and is used to treat Varicose Veins.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
C05BB04
CAS registry number (Chemical Abstracts Service)
0000139-88-8
Chemical Formula
C14-H29-Na-O4-S
Molecular Weight
316
Therapeutic Categories
Agent for local antivaricose therapy
Sclerosing agent
Chemical Name
1-Tetradecanol, hydrogen sulfate, sodium salt
Foreign Names
- Natrii tetradecylis sulfas (Latin)
- Natrium tetradecylsulfat (German)
- Tétradécyl sulfate de sodium (French)
- Tetradecilsulfato sodico (Spanish)
Generic Names
- Sodium myristyl sulfate (IS)
- Sodium tetradecyl sulphate (IS)
- Tergitol 4 (IS)
- Tetradecylhydrogensulfat, Natriumsalz (IS)
- Sodium Tetradecyl Sulphate Concentrate (PH: BP 2011)
Brand Names
- Citobal Compositum (Sodium Tetradecyl Sulfate and Tetracosactide)
Medco, Peru - Fibro Vein
Australasien, Australia; Craveri, Argentina; Mac Pharma, Italy; NZMS, New Zealand; STD Pharmaceutical, United Kingdom - Fibro-Vein
Omnimed, South Africa; STD, Malta; STD Pharmaceutical, United Kingdom - Sotradecol
Bioniche, United States - Trombovar
Kreussler, France
International Drug Name Search
Glossary
| Term | Definition |
|---|---|
| IS | Inofficial Synonym |
| PH | Pharmacopoeia Name |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
